Mineral And Bone Disorder Treatment Market Outlook 2025 – Insights for Executive and Strategic Planning
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Mineral And Bone Disorder Treatment Market Grown from 2024 to 2025?#_x000D_
Recent years have seen a robust growth in the market size for mineral and bone disorder treatment. It is projected to continue its growth from $3.3 billion in 2024 to $3.55 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.7%. This significant progression in the historic period was facilitated by factors such as chronic kidney disease, the aging population, increased awareness about mineral and bone disorders, greater accessibility to treatments of these disorders, and a rise in disposable income levels._x000D_
_x000D_
#What Growth Rate Is Anticipated for the Mineral And Bone Disorder Treatment Market in the Coming Years?#_x000D_
The market for treating mineral and bone disorders is projected to experience substantial growth in the coming years, reaching $4.68 billion by 2029 with a compound annual growth rate (CAGR) of 7.1%. The increase within the forecast period can be credited to factors such as growing interest in improving the quality of life, increasing demand for tailored medicine, government investment in health care, and enhanced awareness about early detection benefits. In the timeframe predicted, we can anticipate advancements in the field of medical research and pharmaceuticals, along with an increased emphasis on digital health, biological therapies, telehealth, and remote patient monitoring._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=12956&type=smp_x000D_
_x000D_
#Who Are the Leading Companies in the Mineral And Bone Disorder Treatment Market?#_x000D_
Major companies operating in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA._x000D_
_x000D_
#What Are the Key Drivers of the Mineral And Bone Disorder Treatment Market?#_x000D_
The surge in the elderly populace is predicted to spur the expansion of the mineral and bone disorder treatment market. People aged 65 and over fall in the demographic category often referred as the elderly population. These individuals often suffer muscle and bone density loss, which leads to frailty and diminished strength. Treatments for mineral and bone disorders can help mitigate age-related alterations in muscles, bones, and joints, fortify bones and impede the rate of bone degradation. For example, the House of Commons Library of the UK Parliament, a British governmental entity, stated in July 2024 that by 2022, 12.7 million people or 19% of the UK populace will be 65 or older. By 2072, this statistic is predicted to ascend to 22.1 million, equating to 27% of the population. Hence, the rising elderly demographic is fuelling the expansion of the mineral and bone disorder treatment market. The growing incidence of chronic kidney diseases (CKD) is anticipated to accelerate the expansion of the mineral and bone disorder treatment market. CKD is a long-term, progressive medical condition that causes the kidneys to gradually lose their functional efficacy over time. The objectives of mineral and bone disorder treatment in chronic kidney diseases involve maintaining proper mineral equilibrium, conserving bone health, and decreasing the risk of complications stemming from these imbalances. For example, a US-based medical library, the National Library of Medicine noted in March 2022, that more than 800 million individuals globally or 10% of the total populace are afflicted with chronic kidney disease, a degenerative disorder. As a result, the rising incidence of chronic kidney diseases is contributing to the growth of the mineral and bone disorder treatment market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=12956&type=smp_x000D_
_x000D_
#What Are the Key Market Segments in the Mineral And Bone Disorder Treatment Industry?#_x000D_
The mineral and bone disorder treatment market covered in this report is segmented –_x000D_
_x000D_
1) By Treatment: Diet, Nutrition, Medication, Supplements, Dialysis_x000D_
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy_x000D_
3) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Diet: Calcium-Rich Foods, Vitamin D-Enriched Foods, Phosphorus-Rich Foods_x000D_
2) By Nutrition: Nutritional Counseling, Fortified Food Products, Meal Replacement Programs_x000D_
3) By Medication: Bisphosphonates, Hormonal Therapies, RANK Ligand Inhibitors_x000D_
4) By Supplements: Calcium Supplements, Vitamin D Supplements, Multivitamin Supplements_x000D_
5) By Dialysis: Hemodialysis, Peritoneal Dialysis, Continuous Renal Replacement Therapy (CRRT)_x000D_
_x000D_
#What Are the Latest Trends in the Mineral And Bone Disorder Treatment Market?#_x000D_
Leading firms in the mineral and bone disorder treatment market are striving to solidify their market standing by inventing new products and ensuring their approval. The rise in drug permissions for mineral and bone disorders can be attributed to the growing elderly population and the escalating occurrence of chronic kidney disorders like TYMLOS (abaloparatide), a lab-crafted version of the human parathyroid hormone. For instance, Radius Health Inc., a biopharmaceutical organization based in the US, obtained the approval for TYMLOS (abaloparatide) in December 2022. This parathyroid hormone-related peptide or PTHrP(1-34) analog is used to augment bone density in osteoporosis-prone men with a high fracture risk. It acts as a stimulant for bone growth by selectively triggering the parathyroid hormone 1 receptor (PTH1R) in osteoblasts and osteocytes, thereby enhancing bone formation and density._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#What Are the Key Regional Markets in the Mineral And Bone Disorder Treatment Industry?#_x000D_
North America was the largest region in the mineral and bone disorder treatment market in 2024. The regions covered in mineral and bone disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12956_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the mineral and bone disorder treatment market, and how is it changing globally?_x000D_
2. Who are the major companies in the mineral and bone disorder treatment market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the mineral and bone disorder treatment market right now?_x000D_
4. Which products or customer segments are growing the most in the mineral and bone disorder treatment market?_x000D_
5. What factors are helping or slowing down the growth of the mineral and bone disorder treatment market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
